Editorial: Post-translational modifications of proteins in cancer immunity and immunotherapy

Editorial: Post-translational modifications of proteins in cancer immunity and immunotherapy

Bibliographic Details
Main Authors:	Xiangpeng Dai, Jinfang Zhang, Brian J. North, Jianping Guo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Immunology
Subjects:	post-translational modifications PD-1/PD-L1 tumor microenvironments immune checkpoint cancer immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1006145/full

Similar Items

Editorial: Community series in post-translational modifications of proteins in cancer immunity and immunotherapy, volume II
by: Naoe Taira Nihira, et al.
Published: (2023-09-01)

Regulation of Intrinsic Functions of PD-L1 by Post-Translational Modification in Tumors
by: Naoe Taira Nihira, et al.
Published: (2022-03-01)

Anti-Tumor Potential of Post-Translational Modifications of PD-1
by: Xiaoming Xi, et al.
Published: (2024-03-01)

The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
by: Linda Quatrini, et al.
Published: (2020-11-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Metabolic Modifications, Inflammation, and Cancer Immunotherapy
by: Sihao Zheng, et al.
Published: (2021-09-01)

Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms
by: Arta M. Monjazeb, et al.
Published: (2021-02-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
by: Ruby Dhar, et al.
Published: (2023-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
by: Zhanjun Guo, et al.
Published: (2022-03-01)

Cancer immunotherapies targeting the PD-1 signaling pathway
by: Yoshiko Iwai, et al.
Published: (2017-04-01)

Challenges and Opportunities for Effective Cancer Immunotherapies
by: Clare Y. Slaney, et al.
Published: (2020-10-01)

Intestinal microbiota: a new force in cancer immunotherapy
by: Zhujiang Dai, et al.
Published: (2020-06-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
by: Adel Naimi, et al.
Published: (2022-04-01)

Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
by: Yao Jiang, et al.
Published: (2023-06-01)

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
by: Seyed Hossein Kiaie, et al.
Published: (2023-09-01)

The Role of Immunotherapy in Pancreatic Cancer
by: Reetu Mukherji, et al.
Published: (2022-09-01)

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
by: Grace Wakabayashi, et al.
Published: (2019-12-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)

Immunotherapy in genitourinary malignancies
by: Kathan Mehta, et al.
Published: (2017-04-01)

The Immune Checkpoint Receptor CD96: A Local and Systemic Immune Modulator in Oral Cancer?
by: Leah Trumet, et al.
Published: (2023-04-01)

Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
by: Kenneth K. W. To, et al.
Published: (2023-08-01)

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
by: Julie M. Collins, et al.
Published: (2018-08-01)

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
by: Luyao Wang, et al.
Published: (2023-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01)

Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years
by: Andreas Koulouris, et al.
Published: (2021-02-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
by: Juwon Lee, et al.
Published: (2021-07-01)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
by: Tingxuan Gu, et al.
Published: (2023-05-01)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
by: Huiyu Yan, et al.
Published: (2023-10-01)

The Association between Blood Indexes and Immune Cell Concentrations in the Primary Tumor Microenvironment Predicting Survival of Immunotherapy in Gastric Cancer
by: Jiajia Yuan, et al.
Published: (2022-07-01)

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
by: Xin Cai, et al.
Published: (2021-11-01)

Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
by: Daniele Lecis, et al.
Published: (2019-05-01)

Advances in post-translational modifications of proteins and cancer immunotherapy
by: Yanqing Li, et al.
Published: (2023-08-01)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
by: Georges Gebrael, et al.
Published: (2023-01-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
by: Edyta Zyla, et al.
Published: (2021-08-01)

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
by: Arefeh Zabeti Touchaei, et al.
Published: (2024-03-01)

Role of immunotherapy in bladder cancer
by: Logan P. Rhea, et al.
Published: (2021-01-01)

Immunotherapy in non-small cell lung cancer: Past, present, and future directions
by: Salman R. Punekar, et al.
Published: (2022-08-01)